10 Best Multibagger Penny Stocks of 2025

5. Autolus Therapeutics plc (NASDAQ:AUTL)

Share Price as of August 29: $3.9

Average Upside Potential as of August 29: 180.6%

Number of Hedge Fund Holders: 24

Autolus Therapeutics plc (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company that develops T-cell therapies to treat cancer and autoimmune diseases. It is based in London, United Kingdom.

The company has been working on growing partnerships with other healthcare players to drive up its capital. One such collaboration is with BioNTech, which, coupled with a capital markets transaction, allowed Autolus Therapeutics plc (NASDAQ:AUTL) to add $600 million to its balance sheet in the first quarter. The company is now poised to deliver on the launch of Obe-cel, one of its main products. Through its efforts, Autolus Therapeutics plc (NASDAQ:AUTL) has also secured significant opportunities for future growth and expansion since the company is now transitioning from a development-stage biotech to a commercial-stage one.

Another source of encouragement for Autolus Therapeutics plc (NASDAQ:AUTL) is the fact that Blackstone Life Sciences has a deal with the company to provide up to $250 million in financing for its drug development and commercialization. Blackstone is interested in the company because of its potential to deliver lifesaving treatments to cancer patients. All in all, Autolus Therapeutics plc (NASDAQ:AUTL) is well placed to continue development on a commercial level and thus has immense upside potential, according to analysts.

Autolus Therapeutics plc (NASDAQ:AUTL) had 24 hedge funds long its stock in the second quarter, with a total stake value of $207.4 million.